文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌的当代分期:准确性与局限性

Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations.
PubMed 文献 · Eur Urol Oncol · 2022-05-14

本文为非系统性综述,总结肌层浸润性膀胱癌(MIBC)分期的现有组成与局限。约50%行根治性膀胱切除术(RC)的患者术前临床分期偏低。传统CT对原发肿瘤分期准确性有限,MRI联合膀胱影像报告与数据系统(VI-RADS)在pT分期上表现出更优准确性;PET/CT未在CT或MRI基础上提高临床淋巴结分期准确性,且PET在常规临床分期中尚无共识性作用。

要点

  • 约50%行RC的MIBC患者术前临床分期偏低。
  • 完整内镜下切除可见病灶并取材至肌层是分期的指征。
  • MRI联合VI-RADS在pT分期上准确性优于传统CT。

核心结论

  • 在缺乏可靠生物标志物作为分期辅助手段的情况下,MIBC分期仍高度依赖TUR联合准确病理评估、麻醉下双合诊(EUA)和标准横断面影像。
  • MRI在原发肿瘤分期方面显示出有前景的准确性和观察者间可靠性。

研究设计与样本

  • 非系统性文献综述,总结MIBC分期准确性的数据,并提供关于当前和新兴MIBC分期标准的专家意见。

主要发现

  • 近50%接受RC的患者术前临床分期偏低。
  • 传统CT在区分非MIBC与MIBC方面准确性有限。
  • MRI联合已验证的膀胱影像报告与数据系统(VI-RADS)在pT分期上表现出更优准确性。
  • PET/CT未在CT或MRI基础上提高临床淋巴结分期准确性。
  • 肿瘤大小、多灶性、变异组织学分化及淋巴血管侵犯等组织学特征有预后价值,但证据不足以纳入当前分期体系。

关键数值与推荐

  • 临床分期组成包括TUR标本评估、麻醉下双合诊(EUA)及胸部、腹部和盆腔横断面影像。
  • 完整内镜下切除可见病灶并取材至肌层是指征。
  • PET在常规临床分期中无共识性作用。

临床怎么用

  • MIBC的有效临床分期可评估局部和全身疾病负荷,并决定全身治疗和/或根治性膀胱切除术的适用性。
  • 当前实践继续依赖TUR联合准确病理评估、EUA和标准横断面影像进行分期。
  • MRI在原发肿瘤分期方面显示出有前景的准确性和观察者间可靠性。

局限性

  • 本文为非系统性综述。
  • 缺乏可靠生物标志物作为分期辅助手段。
  • 组织学特征纳入当前分期体系的证据不足。
  • PET在常规临床分期中无共识性作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Bladder cancer prognosis and treatment are heavily dependent on accurate staging. Traditional imaging and pathologic evaluation of transurethral resection (TUR) specimens have been associated with high rates of clinical understaging at the time of radical cystectomy (RC). OBJECTIVE: We describe current components and limitations of bladder cancer staging for muscle-invasive bladder cancer (MIBC), and discuss the rationale for inclusion of novel biomarkers and imaging modalities to improve diagnostic accuracy. EVIDENCE ACQUISITION: We summarize the data informing MIBC staging accuracy using a nonsystematic review of published literature and provide expert opinion on current and emerging standards in MIBC staging. EVIDENCE SYNTHESIS: Nearly 50% of patients undergoing RC are clinically understaged preoperatively. Components of clinical staging include TUR specimen evaluation, bimanual examination under anesthesia (EUA), and cross-sectional imaging of the chest, abdomen, and pelvis. Complete endoscopic resection of visible disease with sampling of muscularis propria is indicated. While histologic features such as tumor size, focality, variant histologic differentiation, and lymphovascular invasion have prognostic utility, insufficient evidence exists to incorporate them into current staging paradigms. For primary tumor staging, conventional computed tomography (CT) has limited accuracy in differentiating non-MIBC from MIBC. Magnetic resonance imaging (MRI) has exhibited superior pT staging accuracy with the validated Vesical Imaging Reporting and Data System. Positron emission tomography (PET)/CT does not increase clinical nodal staging accuracy beyond CT or MRI, and there exists no consensus role for the use of PET in routine clinical staging. CONCLUSIONS: In the absence of reliable biomarkers to serve as staging adjuncts, we continue to rely heavily on basic clinical staging components-TUR with accurate pathologic evaluation, EUA, and standard cross-sectional imaging modalities. MRI shows promising accuracy and interobserver reliability for primary tumor staging. PATIENT SUMMARY: Effective clinical staging for muscle-invasive bladder cancer estimates local and systemic disease burden and can dictate eligibility for systemic therapy and/or radical cystectomy. Herein, we review the accuracy and limitations of current and emerging staging modalities.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Hensley PJ, Panebianco V, Pietzak E, et al. Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. Eur Urol Oncol. 2022. PMID: 35581143. doi:10.1016/j.euo.2022.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。